Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab plus topical corticosteroids for moderate-to-severe atopic dermatitis (Phase 3)
2017-002065-21Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoint: Investigator's Global Assessment (IGA) response at Week 16. Started Dec 2017; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-002065-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002065-21.